10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar - Exact Sciences (NASDAQ:EXAS),
Benzinga The WHO reports that colorectal cancer is the second most fatal cancer around the world. However, it is also the most preventable, with early detection leading to survival rates above 90%. Alarming statistics reveal that new cases of colorectal cancer in individuals under the age of 50 have been steadily rising over the past few decades. Colorectal cancer is now the leading cause of cancer death for Americans between the ages of 20 and 59 years old according to the National Cancer Institute. However, younger adults are not routinely screened for colorectal cancer as it is still relatively uncommon in their age group.
Mainz Biomed MYNZ, a company that specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, has created ColoAlert, an innovative product that addresses the need for easier and more accessible cancer screenings for quick detection and treatment of colorectal cancer. This non-invasive and user-friendly test aims to make colorectal cancer screening fast, simple and precise.
